Life Sciences Services

- BioLogistics Solutions

- BioStorage/BioServices

Life Sciences Products

Total Revenue

4dca22ffec2483656dddc3e8b92348f9fcf22cfa8949c417fcc1331c91e61d50

Cash and cash equivalents (USD, thousands)

Short-term investments (USD, thousands)

Accounts receivable, net (USD, thousands)

Inventories (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Property and equipment, net (USD, thousands)

Operating lease right-of-use assets (USD, thousands)

Intangible assets, net (USD, thousands)

Goodwill (USD, thousands)

Deposits (USD, thousands)

Deferred tax assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable and other accrued expenses (USD, thousands)

Accrued compensation and related expenses (USD, thousands)

Deferred revenue (USD, thousands)

Current portion of operating lease liabilities (USD, thousands)

Current portion of finance lease liabilities (USD, thousands)

Current portion of convertible senior notes, net of discount (USD, thousands)

Current portion of notes payable (USD, thousands)

Current portion of contingent consideration (USD, thousands)

Total current liabilities (USD, thousands)

Convertible senior notes, net of current portion and discount (USD, thousands)

Notes payable, net of current portion (USD, thousands)

Operating lease liabilities, net of current portion (USD, thousands)

Finance lease liabilities, net of current portion (USD, thousands)

Deferred tax liabilities (USD, thousands)

Other long-term liabilities (USD, thousands)

Contingent consideration, net of current portion (USD, thousands)

Total liabilities (USD, thousands)

Total stockholders’ equity (USD, thousands)

Total liabilities and stockholders’ equity (USD, thousands)

5edfddf8381fad366147939e457df35a6955f76ba79616d32d033aa35d052d2f

Number of customers worldwide (customers)

Number of strategic locations (locations)

Number of clinical trials supported globally (clinical trials)

Number of phase 3 clinical trials supported globally (clinical trials)

f21f0124f232c78d7b5b2e993b3e7f605c542f183033e37357c4a786c71857a2

Net loss [USD, thousands]

Depreciation and amortization [USD, thousands]

Amortization of debt discount [USD, thousands]

Unrealized (gain) loss on investments in equity securities [USD, thousands]

Realized (gain) loss on available-for-sale debt securities [USD, thousands]

Stock-based compensation expense [USD, thousands]

Loss on disposal of property and equipment [USD, thousands]

Provision for bad debt [USD, thousands]

Change in contingent consideration [USD, thousands]

Change in operating lease right-of-use assets and lease liabilities [USD, thousands]

Net cash provided by (used in) operating activities [USD, thousands]

Purchases of property and equipment [USD, thousands]

Purchases of short-term investments [USD, thousands]

Sales/maturities of short-term investments [USD, thousands]

Net cash used in investing activities [USD, thousands]

Proceeds from exercise of stock options and warrants [USD, thousands]

Repayment of finance lease liabilities [USD, thousands]

Repayment of note payable [USD, thousands]

Net cash provided by (used in) financing activities [USD, thousands]

Effect of exchange rate changes on cash and cash equivalents [USD, thousands]

Net change in cash and cash equivalents [USD, thousands]

Cash paid for interest [USD, thousands]

Cash paid for income taxes [USD, thousands]

Excess and obsolete inventory [USD, thousands]

Accounts receivable [USD, thousands]

Inventories [USD, thousands]

Prepaid expenses and other current assets [USD, thousands]

Deposits [USD, thousands]

Accounts payable and other accrued expenses [USD, thousands]

Accrued compensation and related expenses [USD, thousands]

Deferred revenue [USD, thousands]

Net deferred tax (asset) liability [USD, thousands]

Patent and trademark costs [USD, thousands]

Software development costs [USD, thousands]

Cash and cash equivalents — beginning of year [USD, thousands]

Cash and cash equivalents — end of year [USD, thousands]

ccb102e2124cd12c486b8c8474a63ef1acf8e3ab1f1cea6858df759ba5066d2b

Americas

- Foreign Customers

EMEA

APAC

70e5a0b8ece3d2b7fb734f83bf44f7fd41967e962b00c580aa0df904bb16e10d

Total Revenue (USD, thousands)

Cost of Revenue (USD, thousands)

Gross Margin (USD, thousands)

Selling, General and Administrative Expenses (USD, thousands)

Engineering and Development Expenses (USD, thousands)

Loss from Operations (USD, thousands)

Investment Income (USD, thousands)

Other Income (Expense), net (USD, thousands)

Provision for Income Taxes (USD, thousands)

Net Loss (USD, thousands)

Paid-in-kind Dividend on Series C Convertible Preferred Stock (USD, thousands)

Net Loss Attributable to Common Stockholders (USD, thousands)

Net Loss per Share - Basic and Diluted (USD)

Weighted Average Shares Outstanding - Basic and Diluted

1aed8466d1e153fdc35f660893bc03a849eae9816a87849d81e51eabd752bc39

Cryoport Inc (CYRX)

Financials